Tango Therapeutics, Inc. TNGX

24.92 0.29 1.18% as of 25 Sep
Market cap
$4.2B
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
— — 0.00 18.34 25.82 25.84 8.02 16.50
P/FCF ratio
— — 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
— — (1,027.12) (40.20) (22.71) (34.36) (9.21) (34.63)
P/B ratio
— — 1.51 1.97 2.57 3.73 1.69 2.97
EV/Sales
— — 0.00 5.23 11.07 16.59 1.89 10.99
EV/EBITDA
— — 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
— — 0.00 (3.16) (2.36) (5.07) (0.60) (4.90)
Current Ratio
— — 4.73 12.10 6.76 7.54 6.98 16.32
Net Debt/EBITDA
— — 3.70 8.48 3.35 2.93 1.75 3.08
Debt/Equity
— — 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— — (20.50%) (30.38%) (36.41%) (40.49%) (57.58%) (37.23%)
ROA
— 0.00% (50.15%) (16.46%) (23.10%) (24.25%) (36.24%) (28.41%)
ROIC
— — 0.00% 0.00% 0.00% 0.00% 0.00% (2,661.91%)
Return on Tangible Assets
— — (33.20%) (12.76%) (32.72%) (32.77%) (55.15%) (29.97%)
Average Days of Receivables
— — 95.35 19.71 29.36 0.00 0.00 0.00
Earnings Yield
— — 0.00% (8.58%) (16.83%) (11.02%) (39.16%) (9.71%)
Free Cash Flow Yield
— — 0.00% (9.03%) (18.19%) (12.66%) (39.19%) (13.60%)
Free Cash Flow per Share
— — 2.16 (0.99) (1.33) (1.26) (1.21) (1.20)
Book value per Share
— — 1.21 5.55 2.84 2.68 1.83 2.98
Free Cash Flow
— — 68.97 (61.36) (116.77) (119.51) (132.25) (139.93)
EV/EBIT
— — 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates